Pelvic organ prolapse and urinary incontinence: AU general practice guide

Pelvic floor disorders — pelvic organ prolapse (POP) and urinary incontinence — affect approximately one in four Australian women, with prevalence rising steeply with age, parity, BMI, and after menopause. Despite being extremely common, these conditions are significantly under-reported: many women consider leaking with cough or a sense of pelvic heaviness an inevitable consequence of childbirth or ageing rather than treatable health conditions.

The core message for general practice: first-line conservative treatment works well for most women. Pelvic floor muscle training supervised by a continence physiotherapist, bladder training, and lifestyle modification produce meaningful improvement in the majority of cases. Pessaries provide high symptom relief for prolapse without surgery. Medications help overactive bladder. Surgery is effective when conservative treatment has not been sufficient — but it is not the starting point.

A. Core clinical — the AU general practice framework

Risk factors

The key risk factors for both POP and urinary incontinence share a common pathophysiology — increased intra-abdominal pressure and/or weakened pelvic floor support:

• Parity, especially vaginal birth (instrumented delivery and perineal trauma add further risk)
• Age and menopause — oestrogen decline alters connective tissue and mucosal quality
• BMI above 25 — each unit increase in BMI increases incontinence risk
• Chronic constipation with straining
• Chronic cough (smoking, asthma, COPD, ACE-inhibitor cough)
• Heavy occupational or recreational lifting
• Previous pelvic surgery — hysterectomy substantially increases risk of vault prolapse
• Connective tissue disorders (Ehlers-Danlos syndrome)
• Family history of prolapse or incontinence

Pelvic organ prolapse — types

POP is classified by compartment:

• Anterior — cystocele (bladder herniation into the anterior vaginal wall) and urethrocele
• Apical — uterine prolapse (intact uterus), or vaginal vault prolapse (post-hysterectomy)
• Posterior — rectocele (rectum herniating into the posterior vaginal wall) and enterocele (small bowel)

The POP-Q (Pelvic Organ Prolapse Quantification) system stages prolapse from 0 (no prolapse) to Stage IV (complete eversion of the vaginal canal). Symptoms, not stage, drive management decisions — many Stage II prolapses are asymptomatic while some Stage I prolapses significantly affect quality of life.

Common symptoms: vaginal bulge or pressure, a sensation of “something coming down,” incomplete bladder or bowel emptying, splinting (manually reducing the prolapse to void or defaecate), sexual discomfort, and low back pressure. Symptoms typically worsen with prolonged standing and improve with lying down.

Urinary incontinence — types

• Stress urinary incontinence (SUI) — leakage with cough, sneeze, laugh, or exercise; caused by urethral sphincter or support failure; accounts for approximately 50% of incontinence presentations in women
• Urgency incontinence / overactive bladder (OAB) — sudden urge to void that is difficult to suppress, often with frequency (>8 voids per day) and nocturia; accounts for approximately 30% of presentations
• Mixed incontinence — features of both SUI and OAB; approximately 20% of presentations
• Overflow incontinence — continuous dribbling with a high post-void residual; less common in women; consider neurological cause, severe POP, post-surgical obstruction, or medication effect
• Functional incontinence — physical or cognitive impairment limits timely toilet access; common in older adults and those with neurological conditions

History and examination

A targeted history covers: onset and duration, leakage pattern (what triggers it), bladder diary findings, impact on daily activities and sexual function, relevant obstetric history (parity, mode of delivery, perineal trauma), current medications (diuretics, ACE inhibitors, antimuscarinics), and prior treatment attempts.

Examination: perform a pelvic examination with the patient asked to cough and perform Valsalva in the semi-recumbent position, then standing if the resting examination is normal — prolapse is consistently more apparent on standing and Valsalva. Assess each compartment using a Sims speculum. Observe for urethral leakage with cough (positive stress test). Per RANZCOG guidelines and RACGP AFP resources, standing examination significantly improves detection.

Investigations

• Bladder diary (3-day minimum) — frequency, volumes, leak episodes, fluid intake; the foundational diagnostic tool
• Urinalysis — exclude urinary tract infection and haematuria before attributing symptoms to OAB
• Post-void residual ultrasound — over 100–150 mL suggests voiding dysfunction; check before prescribing antimuscarinics, which can worsen retention
• Quality of life questionnaires (PFDI-20, ICIQ-UI) — useful for baseline documentation and monitoring treatment response
• Urodynamics — per NICE NG123 and RANZCOG: reserve for cases where surgery is planned, the diagnosis is atypical, or first-line treatment has failed; not indicated for routine initial assessment of typical SUI or OAB

B. Conservative treatment — the evidence foundation

Pelvic floor muscle training

PFMT is the cornerstone of management for SUI, mixed incontinence, and mild-to-moderate POP. Cochrane systematic review evidence confirms effectiveness, and NICE NG123 recommends it as the first treatment offered to women with SUI or OAB.

The critical requirement is correct technique, verified by a continence physiotherapist. Research consistently shows that up to half of women performing unsupervised pelvic floor exercises use incorrect technique — bearing down rather than lifting — which does not improve and may worsen symptoms. A structured program of at least 8–12 weeks is needed before meaningful benefit is established. Biofeedback may assist those who cannot isolate the correct muscles initially.

MBS-funded physiotherapy under an EPC (Chronic Disease Management) plan (item 10961) provides up to 5 subsidised sessions, extendable to demonstrate benefit. The Continence Foundation of Australia maintains a directory of trained continence physiotherapists nationally.

Maintenance exercises are lifelong — benefit reduces if training is discontinued.

Lifestyle

Lifestyle modifications have strong evidence and should accompany all other treatments:

• Weight loss — a 5–10% reduction in body weight produces substantial improvement in both SUI and OAB; the most powerful modifiable lifestyle factor
• Smoking cessation — reduces chronic cough and its mechanical strain on the pelvic floor
• Constipation management — dietary fibre, adequate fluid intake, stool softeners; straining is a major modifiable risk for prolapse progression
• Fluid management — total intake 1.5–2 L/day; do not restrict fluid (concentrated urine irritates the bladder); reduce caffeine, alcohol, and carbonated drinks for OAB
• Bladder training (OAB) — timed voiding, urge suppression techniques (distraction, quick pelvic floor contractions to blunt urgency), gradual interval extension between voids; effective first-line behavioural treatment for urgency

Pessaries for prolapse

A ring, Gellhorn, or donut pessary inserted into the vagina provides mechanical support for prolapsed organs. Cochrane evidence and RANZCOG guidelines confirm approximately 70% symptom relief. NICE NG123 recommends pessary be offered to all women with symptomatic prolapse before surgery is considered.

Pessaries are appropriate at any age, in women who prefer non-surgical management, in those with significant comorbidities, and in those who wish to preserve fertility. Fitting is performed by a GP, continence nurse, or gynaecologist. Follow-up every 3–6 months for removal and cleaning — some patients learn self-management. Topical vaginal oestrogen cream reduces mucosal irritation in postmenopausal users of pessaries.

Vaginal oestrogen (postmenopausal)

Low-dose vaginal oestrogen — estradiol 10 µg (Vagifem), Estring vaginal ring, or estriol cream (Ovestin) — reduces urogenital atrophy and improves urinary symptoms in postmenopausal women. Systemic absorption is minimal at standard doses. Per eTG and RACGP guidance, vaginal oestrogen is safe in most women with a history of breast cancer; specialist consultation clarifies this in individual cases. It is significantly under-utilised in Australian general practice.

C. Pharmacotherapy and surgical options

Pharmacotherapy for overactive bladder

When bladder training and PFMT have not produced adequate control, medication is appropriate:

Antimuscarinics — oxybutynin, solifenacin (Vesicare), tolterodine, darifenacin, fesoterodine (all PBS Authority Required for OAB). Effective at reducing urgency and frequency. Anticholinergic side effects — dry mouth, constipation, blurred vision, urinary retention — limit tolerability. In older adults, cumulative anticholinergic burden is associated with cognitive impairment and increased dementia risk; minimise use in this population and review all concurrent anticholinergic medications.

Mirabegron (Betmiga) — β3-adrenoceptor agonist; PBS Authority Required for OAB. Equally effective with substantially fewer anticholinergic side effects. Preferred in older patients with cognitive concerns or existing anticholinergic burden. May modestly raise blood pressure; monitor. Cost may be higher than antimuscarinics.

Combination of antimuscarinic and mirabegron for refractory OAB — specialist initiation.

For SUI, no pharmacotherapy has demonstrated meaningful benefit; pelvic floor physiotherapy and, where needed, surgery remain the management pathway.

Surgical options

Surgery is considered when conservative treatment has been adequately trialled and symptoms significantly affect quality of life:

Stress urinary incontinence:

• Mid-urethral sling (tension-free vaginal tape / TVT, or trans-obturator tape / TOT) — gold standard for refractory SUI; NICE NG123 confirms approximately 85–90% success rates. Uses a synthetic mesh tape — distinct from the transvaginal mesh kits withdrawn from the Australian market (see D. Australian operations). Informed consent about mesh-specific complications (erosion, dyspareunia, chronic pain) is mandatory.
• Autologous fascial sling — uses the patient’s own rectus fascia; avoids synthetic material; longer recovery period.
• Bulking agents (periurethral injection) — less invasive; lower success rates; suitable for selected patients who decline or are not candidates for sling surgery.

Pelvic organ prolapse repair:

• Anterior colporrhaphy (cystocele), posterior colporrhaphy (rectocele), sacrospinous fixation (apical support), vaginal hysterectomy with apical support for uterine prolapse in women who have completed their family, sacrocolpopexy via laparoscopy or laparotomy (vault prolapse gold standard — uses abdominal mesh with a different safety profile from transvaginal mesh)
• Colpocleisis (vaginal closure) — highly effective, low morbidity option for non-sexually-active older women who decline or are not candidates for reconstructive surgery

Refractory OAB:

• Botulinum toxin (intravesical injection) — specialist procedure; effective; risk of temporary urinary retention requiring intermittent self-catheterisation in a minority
• Sacral nerve stimulation — specialist; effective for both refractory OAB and faecal incontinence; limited Australian centre availability

D. Australian operations

The transvaginal mesh context

This is an important Australian clinical and medico-legal consideration. Following the 2018 Senate Inquiry into complications from transvaginal mesh for pelvic organ prolapse repair, most transvaginal mesh implant kits for prolapse were withdrawn from the Australian market in 2017–2018 by the Australian Commission on Safety and Quality in Health Care. Complications — mesh erosion, chronic pelvic pain, dyspareunia, revision surgery — were found to be seriously underweighted in pre-market assessment.

Mid-urethral slings (TVT/TOT) for stress urinary incontinence continue in Australia and have a different risk profile. Informed consent about mesh-specific risks remains mandatory for sling procedures.

Women who have previously had transvaginal mesh implanted and experience complications should be referred to specialist mesh injury services at major teaching hospitals. The Australian Commission on Safety and Quality provides consumer-facing mesh information. Patient support groups are active in Australia.

MBS items

• Standard consultations: items 23, 36, 44
• Physiotherapy (EPC / Chronic Disease Management): item 10961 (up to 5 sessions)
• Pelvic and abdominal ultrasound: items 55028/55036
• Post-void residual ultrasound: included in above
• Urodynamics: item 11604 (specialist)
• Prolapse repair procedures: items 35630–35636
• Mid-urethral sling (TVT/TOT): item 37044
• Sacrocolpopexy: item 35648
• GPCCMP for chronic condition management: items 965/967
• 75+ Health Assessment: item 707

PBS prescribing

• Vaginal oestrogen (Vagifem, Ovestin, Estring) — General Schedule; affordable
• Antimuscarinics (solifenacin, tolterodine, darifenacin, fesoterodine, oxybutynin) — Authority Required for OAB indication
• Mirabegron (Betmiga) — Authority Required for OAB indication

Continence Foundation of Australia

The Continence Foundation of Australia operates the National Continence Helpline (1800 33 00 66) for patients and clinicians seeking advice, support, and referral to continence services. The Continence Aids Payment Scheme (CAPS) provides financial assistance for eligible patients requiring continence products. Continence nurses are available in major centres and through community nursing services.

E. Special populations

Postmenopausal women — oestrogen decline accelerates changes in pelvic floor connective tissue and urethral/vaginal mucosa. Vaginal oestrogen is safe and effective and addresses urogenital atrophy contributing to incontinence and pessary discomfort. Pessary fitting and PFMT are appropriate at any age and should be offered as first-line options.

Postpartum — the postpartum period carries the highest risk for new pelvic floor injury. PFMT initiated in pregnancy and continued postpartum is the primary prevention pathway. Significant SUI or prolapse symptoms persisting at 6–12 weeks postpartum warrant referral to a continence physiotherapist. The majority of early postpartum prolapse symptoms improve substantially over the first 6–12 months as pelvic floor healing progresses.

Older adults — surgical risk is higher; colpocleisis for non-sexually-active women offers excellent symptom relief with lower operative risk than reconstructive surgery. Anticholinergic burden is a major safety concern; mirabegron is strongly preferred in older adults. Functional incontinence due to reduced mobility or cognitive impairment is common and requires practical management (toilet accessibility, continence aids, carer support) rather than bladder-directed therapy alone.

Neurological conditions — multiple sclerosis, Parkinson’s disease, spinal cord injury, and diabetic autonomic neuropathy all affect bladder function in distinct ways. Bladder dysfunction may not follow the typical SUI or OAB pattern. Management should include the relevant neurology or rehabilitation team; urodynamics is more likely to be indicated in neurological incontinence.

When to escalate

Refer urgently (same week) for:

• Haematuria — to exclude bladder malignancy before attributing urinary symptoms to OAB; cystoscopy and imaging are required
• Acute urinary retention or very high post-void residual (overflow incontinence)
• Suspected urinary or faecal fistula (continuous leakage without urge, often post-surgical or post-radiotherapy)
• Mesh complication — erosion, chronic pelvic pain, or dyspareunia in a woman who has had prior mesh surgery

Refer routinely:

• To a continence physiotherapist for PFMT instruction before any surgical referral, unless the patient declines conservative treatment
• To urogynaecology or gynaecology for symptomatic prolapse where conservative management has been trialled and failed, or for surgical assessment of SUI in a woman who has completed her family
• To a urologist for refractory OAB, botulinum toxin therapy, sacral nerve stimulation, or male incontinence overlap

What this article is and is not

This is general health information based on current Australian guidelines — RANZCOG, eTG pelvic floor modules, RACGP AFP resources, Continence Foundation of Australia, NICE NG123, and Cochrane reviews. It is not personal medical advice and does not create a doctor–patient relationship. Assessment and management decisions — including whether surgery is appropriate and which procedure — are made with your own GP, gynaecologist, or urogynaecologist.

For support and referral: Continence Foundation of Australia National Continence Helpline 1800 33 00 66, HealthDirect — pelvic organ prolapse, Better Health Channel.

---

Sources cited

1. RANZCOG — Management of Pelvic Organ Prolapse 2024
2. Continence Foundation of Australia
3. NICE NG123 — Urinary incontinence and pelvic organ prolapse in women
4. Cochrane — Pelvic floor muscle training for urinary incontinence
5. Therapeutic Guidelines (eTG) — Pelvic floor disorders
6. RACGP — Pelvic floor disorders in general practice (AFP)
7. Australian Commission on Safety and Quality in Health Care — Mesh complications
8. International Continence Society (ICS)
9. HealthDirect — Pelvic organ prolapse
10. Better Health Channel